Advances in Squamous Cell Carcinoma Antigen and Cervix Cancer Relationship

IF 0.1 Q4 MEDICINE, GENERAL & INTERNAL
B. H. Hamoud, D. Georgescu, A. Călinoiu, I. A. Vacaroiu, M. Georgescu
{"title":"Advances in Squamous Cell Carcinoma Antigen and Cervix Cancer Relationship","authors":"B. H. Hamoud, D. Georgescu, A. Călinoiu, I. A. Vacaroiu, M. Georgescu","doi":"10.55453/rjmm.2023.126.1.2","DOIUrl":null,"url":null,"abstract":"The squamous cell carcinoma antigen is a tumor marker that is receiving more interest due to its biological properties and importance in both pathological and normal physiological processes. Numerous clinical studies have been conducted to determine the potential function of squamous cell carcinoma antigen and its isoform complexes in clinical practice. These studies have been prompted by the fact that not only squamous cell carcinoma antigen but also circulating immune complexes of it and immunoglobulin M are involved in normal physiological and pathological processes. The therapeutic use of squamous cell carcinoma antigen as a tumor marker for either squamous carcinoma diagnosis or for monitoring the response to radiation or chemotherapy, tumor recurrence, and treatment failure are supported by prior investigations. The diagnostic or prognostic utility of squamous cell carcinoma antigen is debatable, nevertheless, as these investigations provide conflicting findings. A uniform detection method, scoring system, and cutoff level must be devised to limit clinical variability between studies and to provide a more accurate and trustworthy comparison of data. Additionally, even if the effectiveness of several approaches is equivalent, only one method should be used for the dynamic monitoring of tumor marker kinetics.","PeriodicalId":21298,"journal":{"name":"Romanian Journal of Military Medicine","volume":"1 1","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2023-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Romanian Journal of Military Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55453/rjmm.2023.126.1.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

The squamous cell carcinoma antigen is a tumor marker that is receiving more interest due to its biological properties and importance in both pathological and normal physiological processes. Numerous clinical studies have been conducted to determine the potential function of squamous cell carcinoma antigen and its isoform complexes in clinical practice. These studies have been prompted by the fact that not only squamous cell carcinoma antigen but also circulating immune complexes of it and immunoglobulin M are involved in normal physiological and pathological processes. The therapeutic use of squamous cell carcinoma antigen as a tumor marker for either squamous carcinoma diagnosis or for monitoring the response to radiation or chemotherapy, tumor recurrence, and treatment failure are supported by prior investigations. The diagnostic or prognostic utility of squamous cell carcinoma antigen is debatable, nevertheless, as these investigations provide conflicting findings. A uniform detection method, scoring system, and cutoff level must be devised to limit clinical variability between studies and to provide a more accurate and trustworthy comparison of data. Additionally, even if the effectiveness of several approaches is equivalent, only one method should be used for the dynamic monitoring of tumor marker kinetics.
鳞状细胞癌抗原与宫颈癌关系的研究进展
鳞状细胞癌抗原是一种肿瘤标志物,由于其生物学特性和在病理和正常生理过程中的重要性而受到越来越多的关注。为了确定鳞状细胞癌抗原及其异构体复合物在临床中的潜在功能,已经进行了大量的临床研究。这些研究是由于鳞状细胞癌抗原不仅参与正常的生理和病理过程,而且其循环免疫复合物和免疫球蛋白M也参与正常的生理和病理过程。将鳞状细胞癌抗原作为肿瘤标志物用于诊断鳞状细胞癌或监测放疗或化疗反应、肿瘤复发和治疗失败,得到了先前研究的支持。然而,鳞状细胞癌抗原的诊断或预后效用是有争议的,因为这些调查提供了相互矛盾的结果。必须设计统一的检测方法、评分系统和截止水平,以限制研究之间的临床变异性,并提供更准确、更可信的数据比较。此外,即使几种方法的有效性是相等的,也应该只使用一种方法来动态监测肿瘤标志物动力学。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Romanian Journal of Military Medicine
Romanian Journal of Military Medicine MEDICINE, GENERAL & INTERNAL-
自引率
33.30%
发文量
2
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信